IMR Press / FBL / Volume 17 / Issue 1 / DOI: 10.2741/3919

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Review
Epigenetic mechanisms of plant-derived anticancer drugs
Show Less
1 Division Experimental Tumorpathology, Institute for Pathology, University Erlangen-Nuremberg, Erlangen, Germany
2 Biology Department, American University of Beirut, Beirut, Lebanon
3 Biology Department, United Arab Emirates (UAE) University, AlAin, UAE
Front. Biosci. (Landmark Ed) 2012, 17(1), 129–173; https://doi.org/10.2741/3919
Published: 1 January 2012
Abstract

Epigenetic mechanisms are essential for normal development and maintenance of adult life. Disruption of epigenetic processes results in deregulated gene expression and leads to life-threatening diseases, in particular, cancer. Global epigenetic alterations are a hallmark of cancer. Cancer epigenetics revealed the deregulation of all components of the epigenetic machinery including DNA methylation, histone modifications, chromatin structure, and non-coding RNAs. Drugs targeting epigenetic processes, or "epi-drugs", are at the forefront of drug discovery, and plant-derived compounds have shown promise. Most of the plant-derived anticancer drugs that work through epigenetic mechanisms are polyphenols; the others are alkaloids, organosulfur compounds, and terpenoids. This review focuses on the epigenetic machinery and its basis for cancer therapy, highlights plant-derived anticancer drugs with epigenetic mechanisms of action, and discusses their potential use in epigenetic therapy.

Keywords
Anticancer drug
Plant-derived
Epigenetic
DNA methylation
Histone modification
Combination treatment
Epigenetic drug dosage
Review
Share
Back to top